HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

Results suggest new hope for patients with refractory chronic lymphocytic leukemia Data to support BLA submission

BARCELONA, SPAIN, June 12 ---ILEXTM Oncology, Inc. (NASDAQ: ILXO) and LeukoSite, Inc. (NASDAQ: LKST) today announced final results from an international, multi-center, pivotal Phase II clinical trial of CAMPATHR for the treatment of patients with B-cell chronic lymphocytic leukemia (CLL) who are refractory to fludarabine. Results of the trial were presented this weekend at the 4th Congress of the European Haematology Association (EHA) by Michael J. Keating, MB, BS, of the M.D. Anderson Cancer Center, one of the trial's principal investigators and an internationally recognized expert in CLL. The companies plan to submit a Biologics License Application (BLA) based largely on these results later this year.

"The results of this trial are encouraging," said Dr. Keating, Associate Head for Clinical Research and Professor of Medicine and internist for the Department of Leukemia at M.D. Anderson Cancer Center. "The data suggest that CAMPATH may provide an important new treatment option for fludarabine-refractory patients, a group for whom the prognosis has, to date, been extremely poor. While the treatment of patients with leukemia has relied on chemotherapeutic agents, the use of monoclonal antibodies is an innovative approach to circumventing the disease's mechanisms for resistance."

The non-comparative trial, involved 93 previously treated patients who had received prior alkylating agents and failed fludarabine therapy (median of three prior treatment regimens). For these patients, the median life expectancy is usually six to nine months.

In the trial, patients participating at the 20 clinical sites in the United States and Europe received 30 mg of CAMPATH on an outpatient basis, as an intravenous infusion, three times a week, for four to 12 weeks. The dose was gradually escalated over the first week to 30 mg, in or
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:4/20/2015)... (PRWEB) April 20, 2015 Early registration ... hurry and secure your space at the start line. ... the Olympic-distance race is limited to 500 participants (actually there’s ... already secured his spot). , Now thru April 30, the ... relay team members; after May 1st, the fee goes up ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 Genuine fat loss ... diets and gym memberships in the past. But what failed ... results can be guaranteed by adhering to five simple ... diet. No matter how many hours one spends working at ... to lose weight., But a nutritional mean plan does not ...
(Date:4/20/2015)... 20, 2015 “ Verus ” was ... Report, which features the latest and coolest technology products ... special reporter for NewsWatch, conducted the review and shared ... variety of purposes. , According to CNET, at least ... in 2013. It’s unfortunate that smartphones break so easily, ...
(Date:4/20/2015)... Clara, CA (PRWEB) April 20, 2015 ... CA and were united as one until 1995. The group ... elements including blues, reggae, rock, bluegrass, folk, space rock, country, ... become known as the ultimate jam band. The group was ... 1994 and in total has sold more than 35 million ...
(Date:4/20/2015)... Tympani Inc., an IT consulting and ... services business 175% this year. Tympani offers a ... to its traditional IT infrastructure, communications and managed ... cloud partners Faction and Seagate Technology, will present ... a Cloud Symposium on April 23 in Rosemont, ...
Breaking Medicine News(10 mins):Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 2Health News:Hilo Triathlon Kicks Up Its Heels A Second Time; Early Bird Registration Available Online Now. 3Health News:Guarantee Fat Loss Results With 5 Easy Tips 2Health News:Guarantee Fat Loss Results With 5 Easy Tips 3Health News:Attractive and Durable Phone Cases were Featured on NewsWatch Television 2Health News:Grateful Dead Tickets at Levi’s Stadium in Santa Clara: Ticket Down Slashes Grateful Dead Tickets in Santa Clara @ Levi’s Stadium for "Fare Thee Well" 50th Anniversary 2Health News:Tympani Grows Cloud Services Business 175%, Presents Cloud Symposium on April 23 2Health News:Tympani Grows Cloud Services Business 175%, Presents Cloud Symposium on April 23 3
(Date:4/20/2015)... 2015   Spirox Inc., a privately held ... an $18.5 million Series B round of financing led by ... Partners, Correlation Ventures and Western Technology Investment also ... a novel, minimally invasive system to be used ... plastic surgeons to treat patients with nasal obstruction, ...
(Date:4/20/2015)... , Apr. 14, 2015 Research and Markets ... the "US Proton Therapy Outlook - Market Opportunities" ... the US Proton Therapy Outlook: Market Opportunities by the ... be home to almost 29 such centers by 2018, ... Consequently, the market will breach the Billion dollar mark ...
(Date:4/20/2015)... , April 20, 2015   Gateway Rehab ... and Training Institute today expanded its Naloxone: Increasing ... locations.  A $50,000 grant from the Staunton ... project possible.  The yearlong research ... patients and their family members upon completion of ...
Breaking Medicine Technology:Spirox, Inc. Announces Closing of $18.5MM Series B Financing 2Spirox, Inc. Announces Closing of $18.5MM Series B Financing 3United States Proton Therapy Outlook to 2018 - Market Opportunities for the $1.19 Billion Market Featuring IBA, Hitachi, Mevion Medical Systems & Varian 2United States Proton Therapy Outlook to 2018 - Market Opportunities for the $1.19 Billion Market Featuring IBA, Hitachi, Mevion Medical Systems & Varian 3Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 2Gateway Rehab and the Kenneth S. Ramsey, PhD Research and Training Institute expand Naloxone: Increasing Access, Saving Lives research project to outpatient locations 3
Cached News: